Carsten Stephan

List of Publications by Year
in descending order

85 papers	2,896 citations	159585 30 h-index	182427 51 g-index
87 all docs	87 docs citations	87 times ranked	3869 citing authors

#	Article	IF	Citations
1	Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort. Urologia Internationalis, 2022, 106, 878-883.	1.3	10
2	Overexpression of Parkin in clear cell renal cell carcinoma decreases tumor aggressiveness by regulating CKS2 levels. International Journal of Oncology, 2022, 60, .	3.3	2
3	CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC. Cancers, 2022, 14, 1541.	3.7	6
4	Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy. Cancers, 2022, 14, 1560.	3.7	1
5	PHI density prospectively improves prostate cancer detection. World Journal of Urology, 2021, 39, 3273-3279.	2.2	13
6	The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p. Cancer Biomarkers, 2021, 30, 381-393.	1.7	1
7	Use of TDI during MRI/US fusion-guided biopsy for suspected prostate cancer. Clinical Hemorheology and Microcirculation, 2021, 78, 259-269.	1.7	2
8	Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies. Urologia Internationalis, 2020, 104, 205-213.	1.3	4
9	Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors. International Journal of Molecular Sciences, 2020, 21, 7812.	4.1	8
10	Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies. Urologia Internationalis, 2020, 104, 181-186.	1.3	12
11	A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature. Cancers, 2019, 11, 1603.	3.7	28
12	Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy. Cancers, 2019, 11, 1473.	3.7	37
13	Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. Radiology, 2019, 292, 250-257.	7.3	40
14	Apelin and apelin receptor expression in renal cell carcinoma. British Journal of Cancer, 2019, 120, 633-639.	6.4	22
15	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e167-e175.	1.9	10
16	Multiparametric Ultrasound (mpUS) of a Rare Testicular Capillary Hemangioma. Case Reports in Radiology, 2019, 2019, 1-5.	0.3	3
17	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. Journal of Urology, 2018, 199, 370-377.	0.4	71
18	UBCÂ® Rapid Testâ€"A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. International Journal of Molecular Sciences, 2018, 19, 3841.	4.1	21

#	Article	IF	Citations
19	Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer. Journal of Urology, 2018, 200, 767-773.	0.4	52
20	Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1992-2003.	2.3	23
21	UBC^{Â®}<i>Rapid</i> Test for detection of carcinoma in situ for bladder cancer. Tumor Biology, 2017, 39, 101042831770162.	1.8	28
22	miRâ€199aâ€3p and miRâ€214â€3p improve the overall survival prediction of muscleâ€invasive bladder cancer patients after radical cystectomy. Cancer Medicine, 2017, 6, 2252-2262.	2.8	31
23	Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?. International Journal of Molecular Sciences, 2017, 18, 2023.	4.1	8
24	Does the Prostate Health Index Depend on Tumor Volume?â€"A Study on 196 Patients after Radical Prostatectomy. International Journal of Molecular Sciences, 2017, 18, 488.	4.1	19
25	Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. International Journal of Molecular Sciences, 2017, 18, 1151.	4.1	35
26	Advances in Biomarkers for PCa Diagnostics and Prognosticsâ€"A Way towards Personalized Medicine. International Journal of Molecular Sciences, 2017, 18, 2193.	4.1	6
27	The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients. Oncotarget, 2017, 8, 79279-79288.	1.8	19
28	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. Oncotarget, 2017, 8, 75076-75086.	1.8	10
29	The percentage of prostateâ€specific antigen (<scp>PSA</scp>) isoform [â€"2]pro<scp>PSA</scp> and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total <scp>PSA</scp> and percentage free <scp>PSA</scp> in men aged â‰65Âyears. BJU International, 2016, 117, 72-79.	2.5	55
30	The translational potential of microRNAs as biofluid markers of urological tumours. Nature Reviews Urology, 2016, 13, 734-752.	3.8	104
31	Patients' perceptions of mortality risk for localized prostate cancer vary markedly depending on their treatment strategy. International Journal of Cancer, 2016, 139, 749-753.	5.1	21
32	Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus. BJU International, 2016, 118, 750-757.	2.5	10
33	Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index. Journal of Urology, 2016, 196, 709-714.	0.4	7
34	TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 345-355.	2.8	39
35	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 2016, 22, 1969-1977.	7.0	170
36	Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p. PLoS ONE, 2016, 11, e0148746.	2.5	88

#	Article	IF	Citations
37	<scp>miRNAs</scp> dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. Journal of Pathology, 2015, 237, 226-237.	4.5	29
38	Glutathione Sâ€transferaseâ€pi protein expression in prostate cancerâ€"not always a useful diagnostic tool. Histopathology, 2015, 67, 577-579.	2.9	4
39	Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. European Urology, 2015, 68, 132-138.	1.9	67
40	Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039. European Urology, 2015, 68, e106-e107.	1.9	6
41	Current biomarkers for diagnosing of prostate cancer. Future Oncology, 2015, 11, 2743-2755.	2.4	15
42	Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer. Anticancer Research, 2015, 35, 2651-5.	1.1	17
43	CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the Prostate. BioMed Research International, 2014, 2014, 1-9.	1.9	13
44	KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. American Journal of Pathology, 2014, 184, 2430-2437.	3.8	69
45	Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer. Clinical Biochemistry, 2014, 47, 916-920.	1.9	3
46	Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 99-112.	7.4	54
47	The effect of [-2]proPSA and prostate health index (phi) on the accuracy of the prediction of initial and repeat prostate biopsies compared to tPSA and percent fPSA in young men (age 65 or younger).. Journal of Clinical Oncology, 2014, 32, 171-171.	1.6	0
48	Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2014, 25, 55-78.	0.7	13
49	Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum [â^'2]Proprostate-Specific Antigenâ€"Based Prostate Health Index for Detection of Prostate Cancer. Clinical Chemistry, 2013, 59, 280-288.	3.2	95
50	Multicenter Evaluation of [â^'2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer. Clinical Chemistry, 2013, 59, 306-314.	3.2	121
51	Use of microRNA signature to distinguish early from late biochemical failure in prostate cancer.. Journal of Clinical Oncology, 2013, 31, 194-194.	1.6	0
52	Use of [-2]proPSA and prostate health index (phi) to improve the diagnostic accuracy of prostate cancer compared to t-PSA and %f-PSA in young men (â‰ 65 years old).. Journal of Clinical Oncology, 2013, 31, 5074-5074.	1.6	0
53	Between-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms. Clinical Chemistry, 2011, 57, 995-1004.	3.2	28
54	Internal validation of an artificial neural network for prostate biopsy outcome. International Journal of Urology, 2010, 17, 62-68.	1.0	10

#	Article	IF	Citations
55	20â€"25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials â€" Analysis of 1098 Patients in Four Centers. International Journal of Biological Markers, 2009, 24, 65-69.	1.8	2
56	Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1325-31.	2.3	28
57	A [â€2]proPSAâ€based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate, 2009, 69, 198-207.	2.3	85
58	20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials â€" analysis of 1098 patients in four centers. International Journal of Biological Markers, 2009, 24, 65-69.	1.8	21
59	New markers and multivariate models for prostate cancer detection. Anticancer Research, 2009, 29, 2589-600.	1.1	20
60	Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity. BMC Urology, 2008, 8, 10.	1.4	5
61	Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clinical Chemistry and Laboratory Medicine, 2008, 46, 623-9.	2.3	25
62	Comparison of Two Different Artificial Neural Networks for Prostate Biopsy Indication in Two Different Patient Populations. Urology, 2007, 70, 596-601.	1.0	18
63	PSA and other tissue kallikreins for prostate cancer detection. European Journal of Cancer, 2007, 43, 1918-1926.	2.8	72
64	PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Letters, 2007, 249, 18-29.	7.2	58
65	Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU International, 2007, 99, 1427-1431.	2.5	30
66	Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2â€"10Âng/ml in 4,480 men. World Journal of Urology, 2007, 25, 95-103.	2.2	22
67	Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update. Clinical Chemistry, 2006, 52, 59-64.	3.2	136
68	Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate, 2006, 66, 651-659.	2.3	37
69	Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. International Journal of Urology, 2006, 13, 238-243.	1.0	34
70	A (-5, -7) ProPSA Based Artificial Neural Network to Detect Prostate Cancer. European Urology, 2006, 50, 1014-1020.	1.9	35
71	Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biological Chemistry, 2006, 387, 801-805.	2.5	20
72	Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU International, 2005, 96, 521-527.	2.5	28

#	Article	IF	Citations
73	The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer, 2005, 104, 993-1003.	4.1	51
74	Hepsin is Highly Over Expressed in and a New Candidate for a Prognostic Indicator in Prostate Cancer. Journal of Urology, 2004, 171, 187-191.	0.4	117
75	Comparison of Eight Computer Programs for Receiver-Operating Characteristic Analysis. Clinical Chemistry, 2003, 49, 433-439.	3.2	122
76	Quantitative analysis of kallikrein 15 gene expression in prostate tissue. Journal of Urology, 2003, 169, 361-4.	0.4	18
77	Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology, 2002, 59, 2-8.	1.0	72
78	An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. International Journal of Cancer, 2002, 99, 466-473.	5.1	49
79	Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clinical Chemistry, 2002, 48, 1279-87.	3.2	44
80	A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Prostate, 2001, 47, 77-84.	2.3	12
81	Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?. International Journal of Cancer, 2001, 93, 759-765.	5.1	28
82	Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. International Journal of Cancer, 2000, 85, 801-804.	5.1	52
83	The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer, 1997, 79, 104-109.	4.1	85
84	The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer, 1997, 79, 104-109.	4.1	3
85	The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume. , 1996, 67, 461-462.		3